Pharmaceutical ProductCached Profile
OMNIPOD
Active Ingredients (Generic):Unmapped
Therapeutic Area: Insulin Pump
LIFETIME PROMOTIONAL SPEND
$350,331
General Payments Aggregated (2021–2025)
Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes
COMPLETEDPhase NANCT04176731
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients
COMPLETEDPhase PHASE2NCT01749137
An Open-label, Multi-centre, Randomised Controlled Trial to Assess the Efficacy, Safety and Utility of Automated Insulin Delivery in People With Type 2 Diabetes and Sub-optimal Glycaemia Undergoing Haemodialysis
NOT_YET_RECRUITINGPhase NANCT07422532
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes
COMPLETEDPhase NANCT05815342
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. WAYNE FREDERICKMedical Doctor$25,000
Dr. MELISSA STEMBRIDGENurse Practitioner$11,792
Dr. ANITA SWAMYMedical Doctor$5,748
Dr. MARTHA CARRANZANurse Practitioner$4,066
Dr. MARTIN SARKARDoctor of Osteopathy$3,914
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2025
2025
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for OMNIPOD...